Literature DB >> 27623276

Anterior Leaflet Augmentation With CorMatrix Porcine Extracellular Matrix in Twenty-Five Patients: Unexpected Patch Failures and Histologic Analysis.

Thomas M Kelley1, Mohammed Kashem2, He Wang2, James McCarthy2, Nels D Carroll2, G William Moser2, T Sloane Guy3.   

Abstract

BACKGROUND: This study reported on the treatment of Carpentier type IIIa and type IIIb mitral regurgitation (MR) with a large patch anterior mitral valve leaflet augmentation technique using CorMatrix (CorMatrix Cardiovascular Inc, Alpharetta, GA) extracellular matrix (ECM).
METHODS: A single-site chart review was conducted on patients who underwent anterior leaflet augmentation performed with the Da Vinci surgical robot (Intuitive Surgical, Sunnyvale, CA) or through a median sternotomy. Only patients who had anterior leaflet augmentation with porcine intestine ECM or autologous pericardium were included. Follow-up echocardiography was performed on all patients. Histologic specimens were available on ECM patches from a subset of patients who required reoperation.
RESULTS: Between August 2011 and April 2014, 44 patients (mean age, 62.6 ± 12.2 years) underwent anterior leaflet augmentation with either porcine intestinal ECM or autologous pericardium at the Temple University Hospital in Philadelphia. Two (4%) late deaths occurred, one in each group. One patient who underwent ECM augmentation died of non-cardiac-related causes 7 months after discharge as a result of complications of chronic renal failure. The second late death occurred 5 months after discharge because of complications of a stroke in a patient in the pericardial augmentation group. Eight (32%) of the patients with ECM had recurrence of severe MR on echocardiography at an average time of 201 ± 98 days. Seven (28%) patients required reoperation because of failure of the ECM patch including perforation (4%), excessive patch dilation (20%), and suture line dehiscence (4%). In contrast, none of the patients with pericardial augmentation developed severe MR or required operation. Statistical analysis of the patients with ECM augmentation demonstrated no correlation of the following: age; sex; comorbid conditions such as diabetes, chronic obstructive pulmonary disease, and hypertension; left ventricular ejection fraction; surgical approach; annuloplasty size; or type of MR with patch failure. A lower body mass index was the only factor associated with recurrent severe regurgitation on univariate analysis (p = 0.039). Histologic study of the four available explants demonstrated intense inflammation without evidence of host integration. The remaining 15 (60%) patients had normal mitral leaflet structure and function on follow-up echocardiograms out to 12 months.
CONCLUSIONS: For type III MR, a large anterior leaflet patch technique with porcine ECM was associated with a 32% recurrence rate of severe MR related directly to patch failure. Further research and development should be performed on the use of ECM materials with a goal to decrease the failure rate experienced in this study.
Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27623276     DOI: 10.1016/j.athoracsur.2016.05.090

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  10 in total

Review 1.  Bioengineering Human Tissues and the Future of Vascular Replacement.

Authors:  Mehmet H Kural; Yuling Li; Juan Wang; Kaleb M Naegeli; Emmanuelle A Hugentobler; Laura E Niklason
Journal:  Circ Res       Date:  2022-06-23       Impact factor: 23.213

2.  Structural Isomerism of the Aortic Valve: Bicuspidization Redux.

Authors:  Thomas G Gleason
Journal:  Ann Thorac Surg       Date:  2019-12-19       Impact factor: 4.330

3.  Annular and subvalvular dynamics after extracellular matrix mitral tube graft implantation in pigs.

Authors:  Marcell J Tjørnild; Lisa Carlson Hanse; Søren N Skov; Karen B Poulsen; Mona Sharghbin; Leila L Benhassen; Diana M Røpcke; Sten L Nielsen; J Michael Hasenkam
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-05-27

4.  Porcine mesothelium matrix as a biomaterial for wound healing applications.

Authors:  H Capella-Monsonís; M A Tilbury; J G Wall; D I Zeugolis
Journal:  Mater Today Bio       Date:  2020-05-17

5.  Dehiscence and embolization of CorMatrix tricuspid valve replacement in the setting of infective endocarditis: a case report.

Authors:  Anna N Tomdio; Melissa Y Y Moey; Irfan Siddiqui; Assad Movahed
Journal:  Eur Heart J Case Rep       Date:  2018-07-31

6.  Wharton's Jelly-Mesenchymal Stem Cell-Engineered Conduit for Pulmonary Artery Reconstruction in Growing Piglets.

Authors:  Filippo Rapetto; Dominga Iacobazzi; Srinivas A Narayan; Katie Skeffington; Tasneem Salih; Shahd Mostafa; Valeria V Alvino; Adrian Upex; Paolo Madeddu; Mohamed T Ghorbel; Massimo Caputo
Journal:  JACC Basic Transl Sci       Date:  2022-02-23

Review 7.  Early and late results of mitral valve repair with anterior leaflet patch augmentation.

Authors:  Hiromu Kehara; Kenji Minakata; James McCarthy; Gengo Sunagawa; Chirantan Mangukia; Stacey Brann; Huaqing Zhao; Robert Boova; Yoshiya Toyoda
Journal:  Interact Cardiovasc Thorac Surg       Date:  2022-07-09

8.  Is Decellularized Porcine Small Intestine Sub-mucosa Patch Suitable for Aortic Arch Repair?

Authors:  Antonio F Corno; Paul Smith; Laurynas Bezuska; Branko Mimic
Journal:  Front Pediatr       Date:  2018-05-30       Impact factor: 3.418

9.  Extracellular matrix-based biomaterials as adipose-derived stem cell delivery vehicles in wound healing: a comparative study between a collagen scaffold and two xenografts.

Authors:  Héctor Capella-Monsonís; Andrea De Pieri; Rita Peixoto; Stefanie Korntner; Dimitrios I Zeugolis
Journal:  Stem Cell Res Ther       Date:  2020-11-27       Impact factor: 6.832

10.  Pathological Changes of Adult Mitral Valves after Failed CorMatrix ECM Repair.

Authors:  Baidarbhi Chakraborty; He Wang
Journal:  J Clin Transl Pathol       Date:  2021-08-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.